Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2020-06-03 5:03 pm Purchase | 13G | MERUS N V COM MRUS | BIOTECHNOLOGY VALUE FUND L P | 4,990,571 17.2% | 1,820,917 (+57.45%) | View |
2020-06-01 5:37 pm Sale | 13G | BIOLINERX LTD SPONSORED ADR NE BLRX | BIOTECHNOLOGY VALUE FUND L P | 31,242,465 11.8% | -699,915 (-2.19%) | View |
2020-05-29 5:06 pm Purchase | 13G | SURFACE ONCOLOGY INC SURF | BIOTECHNOLOGY VALUE FUND L P | 2,125,650 5.8% | 2,125,650 (New Position) | View |
2020-05-26 4:56 pm Sale | 13G | CALITHERA BIOSCIENCES INC CALA | BIOTECHNOLOGY VALUE FUND L P | 7,090,638 10.1% | -2,469,004 (-25.83%) | View |
2020-05-22 5:22 pm Purchase | 13G | SUTRO BIOPHARMA INC STRO | BIOTECHNOLOGY VALUE FUND L P | 2,368,392 6.6% | 2,368,392 (New Position) | View |
2020-04-17 4:54 pm Purchase | 13D | XOMA CORP COM XOMA | BIOTECHNOLOGY VALUE FUND L P | 4,026,157 36.6% | 12,703 (+0.32%) | View |
2020-04-01 4:53 pm Sale | 13G | CYTOKINETICS INC CYTK | BIOTECHNOLOGY VALUE FUND L P | 3,938,280 6.6% | -3,268,178 (-45.35%) | View |
2020-03-17 9:26 pm Purchase | 13D | XOMA CORP COM XOMA | BIOTECHNOLOGY VALUE FUND L P | 4,013,454 36.4% | 118,277 (+3.04%) | View |
2020-03-16 5:23 pm Purchase | 13G | KURA ONCOLOGY INC KURA | BIOTECHNOLOGY VALUE FUND L P | 2,434,696 5.4% | 436,420 (+21.84%) | View |
2020-03-06 5:29 pm Purchase | 13G | CYTOMX THERAPEUTICS INC CTMX | BIOTECHNOLOGY VALUE FUND L P | 3,188,948 7% | 2,064,465 (+183.59%) | View |
2020-03-04 5:29 pm Unchanged | 13D | CTI BIOPHARMA CORP CTIC | BIOTECHNOLOGY VALUE FUND L P | 12,753,690 19.99% | 0 (Unchanged) | View |
2020-02-19 4:32 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC PIRS | BIOTECHNOLOGY VALUE FUND L P | 5,872,762 10.7% | 365,857 (+6.64%) | View |
2020-02-18 4:35 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | BIOTECHNOLOGY VALUE FUND L P | 2,921,177 9.9% | -161,820 (-5.25%) | View |
2020-02-14 7:57 pm Purchase | 13G | SPERO THERAPEUTICS INC SPRO | BIOTECHNOLOGY VALUE FUND L P | 2,028,405 9.99% | 213,259 (+11.75%) | View |
2020-02-14 5:19 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | BIOTECHNOLOGY VALUE FUND L P | 2,096,708 9.99% | 1,044,768 (+99.32%) | View |
2020-02-14 5:18 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BIOTECHNOLOGY VALUE FUND L P | 2,816,390 9.99% | 280,512 (+11.06%) | View |
2020-02-14 5:06 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | BIOTECHNOLOGY VALUE FUND L P | 1,660,475 9.99% | 368,059 (+28.48%) | View |
2020-02-14 5:00 pm Sale | 13G | ARQULE INC ARQL | BIOTECHNOLOGY VALUE FUND L P | 4,902,383 4% | -3,767,967 (-43.46%) | View |
2020-02-14 5:00 pm Purchase | 13G | GENOCEA BIOSCIENCES INC NE GNCA | BIOTECHNOLOGY VALUE FUND L P | 3,161,668 6.5% | 3,161,668 (New Position) | View |
2020-02-14 4:39 pm Purchase | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | BIOTECHNOLOGY VALUE FUND L P | 11,653,925 9.98% | 7,758,899 (+199.20%) | View |